Opendata, web and dolomites

OncoSeq

OncoSeq: an innovative single-cell system for immunomonitoring

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 OncoSeq project word cloud

Explore the words cloud of the OncoSeq project. It provides you a very rough idea of what is the project "OncoSeq" about.

simultaneous    le    mass    infiltrate    company    phenotypic    molecular    cell    central    once    microfluidics    validated    creation    follow    transcriptomic    plays    tool    cytof    marker    immunotherapies    strategies    industrial    throughput    markets    ultimately    rna    readout    powerful    cells    tens    biopsy    diagnostic    immunity    thousands    phenotype    100s    instruments    seq    context    exist    single    liquid    droplet    clinical    erc    create    quantity    patient    site    fluorescence    decision    flow    tumour    resolution    prognosis    barcoding    maps    cytometer    host    monitoring    prototype    stratification    immunotherapy    evoevo    immune    prognostic    sequencing    immuno    progression    capacity    entirely    quality    licensing    adapt    ngs    plan    specialising    cancer    multiplexing    tumor    oncoseq    transferred    genotype    output    markers    spectrometry    internal    cytometry    sale    disease    diagnosis    vital    transcriptome    oncology    circulating    infiltrating    consumables    generation   

Project "OncoSeq" data sheet

The following table provides information about the project.

Coordinator
PARMENIDES STIFTUNG 

Organization address
address: KIRCHPLATZ 1
city: MUNCHEN
postcode: 82049
website: www.parmenides-foundation.org

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 150˙000 €
 EC max contribution 150˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2017-PoC
 Funding Scheme ERC-POC
 Starting year 2017
 Duration (year-month-day) from 2017-11-01   to  2018-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PARMENIDES STIFTUNG DE (MUNCHEN) coordinator 41˙250.00
2    ECOLE SUPERIEURE DE PHYSIQUE ET DECHIMIE INDUSTRIELLES DE LA VILLE DEPARIS FR (PARIS) participant 108˙750.00

Map

 Project objective

Host immunity plays a central and complex role in tumour progression, and the quality and quantity of immune infiltrate at the tumour site is used as a prognostic marker of cancer progression. Therefore, detailed single-cell analysis of tumor infiltrating immune cells, and ultimately liquid biopsy of circulating immune cells, is of vital importance for the development of new and improved immunotherapy strategies, and for diagnosis, prognosis, patient stratification and follow-up. We propose in OncoSeq to adapt the droplet barcoding microfluidics system, an output from the ERC EVOEVO project, to develop a novel “molecular cytometer” for high-throughput transcriptomic and phenotypic analysis, at the single-cell level, of tumor infiltrating or circulating immune cells. Readout of genotype and phenotype will be entirely based on next generation sequencing (NGS) allowing higher phenotypic multiplexing capacity (100s of phenotypic markers) than fluorescence (Flow cytometry) or mass spectrometry (CyTOF) based approaches (≤40 markers) and simultaneous RNA-sequencing (RNA-seq), allowing the creation of high-resolution phenotype-transcriptome maps for tens of thousands of single cells. This will be a powerful tool for cancer prognosis, clinical decision making and monitoring of disease progression, especially in the context of immunotherapy. So far, no such diagnostic instruments, enabling high-throughput single-cell phenotypic and transcriptomic analysis, exist. The technology developed will be transferred to our industrial partner through licensing for internal development of novel immunotherapies. In addition, once the prototype system is fully validated, we plan, with our industrial partners, to create a new company specialising in the sale of instruments and associated consumables for clinical single-cell immuno-monitoring for the research and clinical oncology markets.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ONCOSEQ" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ONCOSEQ" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

Resonances (2019)

Resonances and Zeta Functions in Smooth Ergodic Theory and Geometry

Read More  

Aware (2019)

Aiding Antibiotic Development with Deep Analysis of Resistance Evolution

Read More  

TRUST (2018)

Truth and Semantics

Read More